367 related articles for article (PubMed ID: 17979893)
1. DLC-1:a Rho GTPase-activating protein and tumour suppressor.
Durkin ME; Yuan BZ; Zhou X; Zimonjic DB; Lowy DR; Thorgeirsson SS; Popescu NC
J Cell Mol Med; 2007; 11(5):1185-207. PubMed ID: 17979893
[TBL] [Abstract][Full Text] [Related]
2. Identifying Cancer-Relevant Mutations in the DLC START Domain Using Evolutionary and Structure-Function Analyses.
Holub AS; Bouley RA; Petreaca RC; Husbands AY
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142932
[TBL] [Abstract][Full Text] [Related]
3. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
Durkin ME; Ullmannova V; Guan M; Popescu NC
Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tumor Suppressor DLC-1: Far From Clear.
Liu X; Pan YJ; Zheng JN; Pei DS
Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
Ullmannova V; Popescu NC
Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
[TBL] [Abstract][Full Text] [Related]
6. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.
Kim TY; Healy KD; Der CJ; Sciaky N; Bang YJ; Juliano RL
J Biol Chem; 2008 Nov; 283(47):32762-70. PubMed ID: 18786931
[TBL] [Abstract][Full Text] [Related]
7. DLC-1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGF-β1 signaling.
Zhang K; Na T; Ge F; Yuan BZ
Exp Cell Res; 2020 Jan; 386(2):111732. PubMed ID: 31770531
[TBL] [Abstract][Full Text] [Related]
8. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
Durkin ME; Avner MR; Huh CG; Yuan BZ; Thorgeirsson SS; Popescu NC
FEBS Lett; 2005 Feb; 579(5):1191-6. PubMed ID: 15710412
[TBL] [Abstract][Full Text] [Related]
9. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.
Feng M; Huang B; Du Z; Xu X; Chen Z
Mol Biol Rep; 2011 Mar; 38(3):1915-20. PubMed ID: 20882354
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
[TBL] [Abstract][Full Text] [Related]
11. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
[TBL] [Abstract][Full Text] [Related]
12. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
[TBL] [Abstract][Full Text] [Related]
13. DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells.
Feng X; Li C; Liu W; Chen H; Zhou W; Wang L; Zhu B; Yao K; Jiang X; Ren C
Int J Oncol; 2013 Jun; 42(6):1973-84. PubMed ID: 23588806
[TBL] [Abstract][Full Text] [Related]
14. StarD13: a potential star target for tumor therapeutics.
Jaafar L; Chamseddine Z; El-Sibai M
Hum Cell; 2020 Jul; 33(3):437-443. PubMed ID: 32274657
[TBL] [Abstract][Full Text] [Related]
15. Rho regulation: DLC proteins in space and time.
Braun AC; Olayioye MA
Cell Signal; 2015 Aug; 27(8):1643-51. PubMed ID: 25889896
[TBL] [Abstract][Full Text] [Related]
16. The DLC-1 tumor suppressor is involved in regulating immunomodulation of human mesenchymal stromal /stem cells through interacting with the Notch1 protein.
Na T; Zhang K; Yuan BZ
BMC Cancer; 2020 Nov; 20(1):1064. PubMed ID: 33148199
[TBL] [Abstract][Full Text] [Related]
17. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
18. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility.
Kim TY; Vigil D; Der CJ; Juliano RL
Cancer Metastasis Rev; 2009 Jun; 28(1-2):77-83. PubMed ID: 19221866
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
20. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
